Market Cap 529.93M
Revenue (ttm) 0.00
Net Income (ttm) -167.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,240,256
Avg Vol 3,502,166
Day's Range N/A - N/A
Shares Out 163.06M
Stochastic %K 5%
Beta 3.21
Analysts Strong Sell
Price Target $13.38

Company Profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythe...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 759 3100
Address:
2929 Arch Street, Suite 600, Philadelphia, United States
robbied61
robbied61 Jun. 8 at 7:17 PM
$CABA it will go below 3 like the death with a thousand stabs i am a buyer data was good it will go higher requires un limited patience 😀
0 · Reply
Moonman321
Moonman321 Jun. 8 at 6:01 PM
$CABA This feels like the final shakeout before liftoff. Testing a major psychological level at $3, creating fear, shaking loose shares, and frustrating investors right before sentiment turns. I’ve seen this movie before. Holding strong. 🚀
0 · Reply
Moonman321
Moonman321 Jun. 8 at 5:59 PM
$CABA The $3 level is more than just a chart level. It’s a psychological level and an important margin threshold that many traders are watching closely. Meanwhile, the company continues to execute. Recent data presentations reinforced the strength of the platform, management continues to advance the pipeline, and the long-term story remains intact. To me, this looks like a classic shakeout around a major support area. Weak hands get nervous, while long-term investors focus on the science, cash position, and upcoming catalysts. The Russell remains strong, small-cap biotech is showing signs of life, and CABA is sitting right at a level where sentiment can change quickly. The story hasn’t changed. The data hasn’t changed. The opportunity hasn’t changed. Holding strong and looking forward to what comes next. 🚀
1 · Reply
ABDULMOHSEN08
ABDULMOHSEN08 Jun. 8 at 5:46 PM
$CABA 😉😉
0 · Reply
ABDULMOHSEN08
ABDULMOHSEN08 Jun. 8 at 5:18 PM
$CABA 1- There is no strong desire to buy, so the volume of sales prevails. 2- Supply exceeds demand due to excessive dilution, therefore there is no real price movement. Note: They tricked you by saying the stock price would reach $30 🙄
1 · Reply
Matthew619
Matthew619 Jun. 8 at 5:17 PM
$CABA This is a gift down here. If it drops I will buy more. If it goes under 3 I’ll double my position. Know what you own.
0 · Reply
Achandler787
Achandler787 Jun. 8 at 4:18 PM
$CABA stocks go up and down 😊 Hopefully up next
0 · Reply
sethgrace
sethgrace Jun. 8 at 3:01 PM
$CABA this guy looks like he was right.
2 · Reply
ABDULMOHSEN08
ABDULMOHSEN08 Jun. 8 at 2:39 PM
$CABA Are they still selling? 🙄
0 · Reply
Viktor4o
Viktor4o Jun. 8 at 2:39 PM
$AMZN $CABA $NVDA $PLUG $TSLA Where are you 🤡🤡🤡???
1 · Reply
Latest News on CABA
Cabaletta Bio Slides: Corporate presentation

Jun 3, 2026, 7:00 AM EDT - 5 days ago

Cabaletta Bio Slides: Corporate presentation


Cabaletta Bio Proxy statement: Proxy filing

Jun 1, 2026, 8:00 AM EDT - 7 days ago

Cabaletta Bio Proxy statement: Proxy filing


Cabaletta Bio presents new clinical data for rese-cel

2026-05-14T14:21:15.000Z - 25 days ago

Cabaletta Bio presents new clinical data for rese-cel


Cabaletta Bio reports Q1 EPS (39c), consensus (39c)

2026-05-14T12:08:57.000Z - 25 days ago

Cabaletta Bio reports Q1 EPS (39c), consensus (39c)


Cabaletta Bio Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 25 days ago

Cabaletta Bio Quarterly report: Q1 2026


Cabaletta Bio Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 25 days ago

Cabaletta Bio Earnings release: Q1 2026


Cabaletta Bio Slides: Corporate presentation

May 14, 2026, 7:00 AM EDT - 25 days ago

Cabaletta Bio Slides: Corporate presentation


Cabaletta Bio, Cellares enter 10-year commercial agreement

2026-04-28T12:38:26.000Z - 5 weeks ago

Cabaletta Bio, Cellares enter 10-year commercial agreement


Cabaletta Bio Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 5 weeks ago

Cabaletta Bio Proxy statement: Proxy filing


Cabaletta Bio Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 5 weeks ago

Cabaletta Bio Proxy statement: Proxy filing


Cabaletta Bio Slides: Corporate presentation

Apr 20, 2026, 7:00 AM EDT - 7 weeks ago

Cabaletta Bio Slides: Corporate presentation


Cabaletta Bio Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 7 weeks ago

Cabaletta Bio Proxy statement: Proxy filing


Cabaletta Bio price target raised to $16 from $15 at Guggenheim

2026-03-23T18:00:24.000Z - 2 months ago

Cabaletta Bio price target raised to $16 from $15 at Guggenheim


Cabaletta Bio reports Q4 EPS (40c), consensus (47c)

2026-03-23T11:40:46.000Z - 2 months ago

Cabaletta Bio reports Q4 EPS (40c), consensus (47c)


Cabaletta Bio Annual report: Q4 2025

Mar 23, 2026, 7:30 AM EDT - 2 months ago

Cabaletta Bio Annual report: Q4 2025


Cabaletta Bio Earnings release: Q4 2025

Mar 23, 2026, 7:30 AM EDT - 2 months ago

Cabaletta Bio Earnings release: Q4 2025


Cabaletta Bio Slides: Corporate presentation

Mar 23, 2026, 7:00 AM EDT - 2 months ago

Cabaletta Bio Slides: Corporate presentation


Cabaletta Bio announces 2026 strategic priorities

2026-01-12T13:38:11.000Z - 5 months ago

Cabaletta Bio announces 2026 strategic priorities


Cabaletta Bio Announces 2026 Strategic Priorities

Jan 12, 2026, 8:00 AM EST - 5 months ago

Cabaletta Bio Announces 2026 Strategic Priorities


Cabaletta Bio Slides: Corporate presentation

Jan 11, 2026, 7:00 AM EST - 5 months ago

Cabaletta Bio Slides: Corporate presentation


Cabaletta Bio Slides: Corporate Presentation

Dec 5, 2025, 7:00 AM EST - 6 months ago

Cabaletta Bio Slides: Corporate Presentation


Cabaletta Bio reports Q3 EPS (44c), consensus (46c)

2025-11-10T12:38:12.000Z - 7 months ago

Cabaletta Bio reports Q3 EPS (44c), consensus (46c)


Cabaletta Bio sees cash runway into 2H26

2025-11-10T12:37:22.000Z - 7 months ago

Cabaletta Bio sees cash runway into 2H26


Cabaletta Bio Quarterly report: Q3 2025

Nov 10, 2025, 7:30 AM EST - 7 months ago

Cabaletta Bio Quarterly report: Q3 2025


Cabaletta Bio Earnings release: Q3 2025

Nov 10, 2025, 7:30 AM EST - 7 months ago

Cabaletta Bio Earnings release: Q3 2025


Cabaletta Bio Registration statement: Registration Filing

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Cabaletta Bio Registration statement: Registration Filing


Cabaletta Bio Quarterly report: Q2 2025

Aug 7, 2025, 7:30 AM EDT - 10 months ago

Cabaletta Bio Quarterly report: Q2 2025


Cabaletta Bio Earnings release: Q2 2025

Aug 7, 2025, 7:30 AM EDT - 10 months ago

Cabaletta Bio Earnings release: Q2 2025


Cabaletta Bio Slides: Investor Presentation

Jun 11, 2025, 7:00 AM EDT - 1 year ago

Cabaletta Bio Slides: Investor Presentation


Cabaletta Bio Quarterly report: Q1 2025

May 15, 2025, 9:30 AM EDT - 1 year ago

Cabaletta Bio Quarterly report: Q1 2025


Cabaletta Bio Proxy statement: Proxy Filing

May 13, 2025, 8:00 AM EDT - 1 year ago

Cabaletta Bio Proxy statement: Proxy Filing


Cabaletta Bio Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Cabaletta Bio Proxy statement: Proxy Filing


Cabaletta Bio Earnings release: Q4 2024

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Cabaletta Bio Earnings release: Q4 2024


Cabaletta Bio Annual report: Q4 2024

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Cabaletta Bio Annual report: Q4 2024


Cabaletta Bio Transcript: Status Update

Nov 18, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio Transcript: Status Update


Cabaletta Bio Press release: Status Update

Nov 18, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio Press release: Status Update


Cabaletta Bio Slides: Status Update

Nov 18, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio Slides: Status Update


Cabaletta Bio Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

Cabaletta Bio Quarterly report: Q3 2024


Cabaletta Bio Earnings release: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

Cabaletta Bio Earnings release: Q3 2024


Cabaletta Bio Quarterly report: Q2 2024

Aug 8, 2024, 7:15 AM EDT - 1 year ago

Cabaletta Bio Quarterly report: Q2 2024


Cabaletta Bio Earnings release: Q2 2024

Aug 8, 2024, 7:15 AM EDT - 1 year ago

Cabaletta Bio Earnings release: Q2 2024


Cabaletta Bio Transcript: Study Update

Jun 14, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Transcript: Study Update


Cabaletta Bio Press release: Study Update

Jun 14, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Press release: Study Update


Cabaletta Bio Slides: Study Update

Jun 14, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Slides: Study Update


Cabaletta Bio Quarterly report: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

Cabaletta Bio Quarterly report: Q1 2024


Cabaletta Bio Earnings release: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

Cabaletta Bio Earnings release: Q1 2024


Cabaletta Bio Slides: Corporate Presentation

May 15, 2024, 7:00 AM EDT - 2 years ago

Cabaletta Bio Slides: Corporate Presentation


Cabaletta Bio Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Proxy statement: Proxy Filing


Cabaletta Bio Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Proxy statement: Proxy Filing


Cabaletta Bio Earnings release: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Earnings release: Q4 2023


Cabaletta Bio Annual report: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Annual report: Q4 2023


Cabaletta Bio Slides: FY 2024

Jan 9, 2024, 8:15 PM EST - 2 years ago

Cabaletta Bio Slides: FY 2024


Cabaletta Bio Quarterly report: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Cabaletta Bio Quarterly report: Q3 2023


Cabaletta Bio Earnings release: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Cabaletta Bio Earnings release: Q3 2023


Cabaletta Bio Quarterly report: Q2 2023

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Cabaletta Bio Quarterly report: Q2 2023


Cabaletta Bio Earnings release: Q2 2023

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Cabaletta Bio Earnings release: Q2 2023


robbied61
robbied61 Jun. 8 at 7:17 PM
$CABA it will go below 3 like the death with a thousand stabs i am a buyer data was good it will go higher requires un limited patience 😀
0 · Reply
Moonman321
Moonman321 Jun. 8 at 6:01 PM
$CABA This feels like the final shakeout before liftoff. Testing a major psychological level at $3, creating fear, shaking loose shares, and frustrating investors right before sentiment turns. I’ve seen this movie before. Holding strong. 🚀
0 · Reply
Moonman321
Moonman321 Jun. 8 at 5:59 PM
$CABA The $3 level is more than just a chart level. It’s a psychological level and an important margin threshold that many traders are watching closely. Meanwhile, the company continues to execute. Recent data presentations reinforced the strength of the platform, management continues to advance the pipeline, and the long-term story remains intact. To me, this looks like a classic shakeout around a major support area. Weak hands get nervous, while long-term investors focus on the science, cash position, and upcoming catalysts. The Russell remains strong, small-cap biotech is showing signs of life, and CABA is sitting right at a level where sentiment can change quickly. The story hasn’t changed. The data hasn’t changed. The opportunity hasn’t changed. Holding strong and looking forward to what comes next. 🚀
1 · Reply
ABDULMOHSEN08
ABDULMOHSEN08 Jun. 8 at 5:46 PM
$CABA 😉😉
0 · Reply
ABDULMOHSEN08
ABDULMOHSEN08 Jun. 8 at 5:18 PM
$CABA 1- There is no strong desire to buy, so the volume of sales prevails. 2- Supply exceeds demand due to excessive dilution, therefore there is no real price movement. Note: They tricked you by saying the stock price would reach $30 🙄
1 · Reply
Matthew619
Matthew619 Jun. 8 at 5:17 PM
$CABA This is a gift down here. If it drops I will buy more. If it goes under 3 I’ll double my position. Know what you own.
0 · Reply
Achandler787
Achandler787 Jun. 8 at 4:18 PM
$CABA stocks go up and down 😊 Hopefully up next
0 · Reply
sethgrace
sethgrace Jun. 8 at 3:01 PM
$CABA this guy looks like he was right.
2 · Reply
ABDULMOHSEN08
ABDULMOHSEN08 Jun. 8 at 2:39 PM
$CABA Are they still selling? 🙄
0 · Reply
Viktor4o
Viktor4o Jun. 8 at 2:39 PM
$AMZN $CABA $NVDA $PLUG $TSLA Where are you 🤡🤡🤡???
1 · Reply
THE_MADMAN
THE_MADMAN Jun. 8 at 2:25 PM
$CABA from the call today it seems like they can get the voucher. Which is worth around 150m
1 · Reply
robbied61
robbied61 Jun. 8 at 1:53 PM
$CABA my opinion hot money didnt get there trade we will seetheml exit i am a buyer below 3
0 · Reply
ABDULMOHSEN08
ABDULMOHSEN08 Jun. 8 at 1:44 PM
$CABA Look at the sales volume 🙄
2 · Reply
PraxisTrade
PraxisTrade Jun. 8 at 10:47 AM
0 · Reply
SignoreRossi
SignoreRossi Jun. 8 at 8:58 AM
$CABA Goldman today for CABA is the immediate focus. Let’s see what they gonna say about BLA timeline and cash runway, if positive I expect a bounce from $3.50 toward $4.00+. Wednesday CPI is the macro wildcard that could influence the price in both directions.
1 · Reply
PraxisTrade
PraxisTrade Jun. 8 at 8:43 AM
$HOVR $CABA jig is up
0 · Reply
ABDULMOHSEN08
ABDULMOHSEN08 Jun. 8 at 3:59 AM
$CABA Hello, today we will be watching a test of levels from 3.25 to 3 dollars or lower.
2 · Reply
Moonman321
Moonman321 Jun. 8 at 2:14 AM
$CABA $NVDA $TSLA $AMZN $PLUG $CABA EULAR data added to an already impressive autoimmune CAR-T dataset. ✅ 50+ evaluable patients across lupus, myositis and systemic sclerosis ✅ Encouraging early preconditioning-free lupus findings ✅ Continued evidence supporting a one-time immune reset approach The science continues to advance while the stock remains heavily oversold. The market may not react immediately, but the dataset keeps expanding, management continues to execute, and the autoimmune opportunity remains massive. This week brings investor conference appearances and the annual shareholder meeting, keeping attention on the story. Watching for increased focus on the growing patient dataset, preconditioning-free lupus program, and the broader small-cap biotech rotation. Sometimes the stock lags the science. Eventually the market catches up. There you go a 10 X stock Mark it !!! Grab some $PLUG also and thank me later  #MegaTechSellOff /rotation 
1 · Reply
Achandler787
Achandler787 Jun. 7 at 10:05 PM
$CABA https://finance.yahoo.com/markets/stocks/articles/cabaletta-bio-inc-caba-top-175854899.html
0 · Reply
christopher18
christopher18 Jun. 7 at 5:07 PM
$CABA The 6-month mark from insider buys is the third week of July. I assume that nothing will trend up till that time. Any movement we had prior to data has sold off. We could easily hit the $3 mark again.
1 · Reply
Achandler787
Achandler787 Jun. 7 at 12:23 PM
$CABA Saturday Eular data and response Positive! Investment response should be the same my opinion.
0 · Reply
Moonman321
Moonman321 Jun. 7 at 2:46 AM
$CABA $CABA Saturday’s EULAR update reinforced the bull thesis. ✅ 52 evaluable patients across multiple autoimmune diseases ✅ Deep B-cell depletion and immune reset observed ✅ Durable responses with patients off immunomodulators ✅ Encouraging juvenile dermatomyositis results ✅ Early lupus data without preconditioning ✅ Systemic sclerosis program advancing toward registrational studies ✅ Favorable safety profile continues Big takeaway: Cabaletta continues to demonstrate that rese-cel may have the potential to treat multiple autoimmune diseases with a single platform while delivering durable responses. This story is evolving from proof-of-concept to potential commercialization. One platform. Multiple diseases. Potential immune reset. 💪🏻
2 · Reply